CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index

Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

Blog

6 tests for assessing cognition in Parkinson’s disease

Cognitive dysfunction in Parkinson’s disease remains a significant, unmet therapeutic need for patients; as such it is vital that there is rigorous research into the topic. Here we will discuss six CANTAB tasks that can address this research gap. 

Exploring participant-level trajectories of cognitive performance in patients with schizophrenia

Cambridge Cognition and Boehringer Ingelheim have been investigating cognitive performance among patients with schizophrenia, with a view to improving future pro-cognitive drug trial designs. Our Director of Neuroscience, Dr Kiri Granger, presented the latest findings at ISCTM and SIRS.

What does the new FDA guidance mean for clinical trials in early Alzheimer’s disease?

The latest FDA draft guidance for clinical trials in early Alzheimer’s disease presents many new opportunities and challenges for drug development. 

Can acetylcholinesterase inhibitors and CNS stimulants tackle cognitive dysfunction in multiple scle

Cognitive dysfunction in multiple sclerosis (MS) presents a significant, unmet therapeutic need. Researchers at Cambridge Cognition and the University of Manchester investigated potential solutions to this problem with a systematic review and meta-analysis of pro-cognitive drug trials in MS. 

How to select sensitive outcome measures in pro-cognitive drug trials for schizophrenia

The outcome measure selected for a pro-cognitive drug trial in schizophrenia must be sensitive enough to detect potentially subtle changes in cognition.

Trial design: 4 ways to improve trials of pro-cognitive drugs in schizophrenia

Discussing the methodological considerations, and suggesting recommendations, for successful pro-cognitive drugs trials in schizophrenia.

Patient recruitment: are you selecting the right patients for schizophrenia clinical trials?

The importance of recruiting patients for pro-cognitive drug trials in schizophrenia on the basis of cognitive dysfunction. 

Improving clinical trials for pro-cognitive drugs in schizophrenia

Introducing a blog-post series to discuss key limitations, and potential improvements, for pro-cognitive drug trials in schizophrenia.

WEBINAR: Overcoming methodological challenges to enhance study success in schizophrenia trials

Dr Kiri Granger, Director of Neuroscience, Cambridge Cognition and Dr Steve Brannan, Chief Medical Officer, ‎Karuna Pharmaceuticals Inc. hosted a webinar on how to improve clinical trial success in schizophrenia.

web-based testing, wearables, voice recognition, virtual clinical trials, transdiagnostic, technology, swm, subjective measures, stigma, social cognition, smartphones, set-shifting, screening, schizophrenia research, schizophrenia, rvp, risk-taking, research funding, research, remote testing, regulations, recruitment, prodromal, pro-cognitive, primary care, presenteeism, precision psychiatry, pre-clinical, personalised medicine, pen-and-paper, patient-centric, patient screening, patient recruitment, parkinson's disease, pal, ots, open access, occupational health, objective measures, novel, normative data, neurotech, neuroscience, near-patient testing, multiple sclerosis, ms, modelling, mental wellbeing, mental health at work, mental health, mci, major depression, longitudinal, inflammation, ied, high frequency, healthcare, guide, funding, ert, epidemiology, emotion recognition, ecoa, ebt, ebbinghaus, early career researchers, early alzheimer's disease, drug development, digital tools, digital health, depression, dementia, cognitive testing, cognitive science, cognitive safety, cognitive impairment, cognitive function, cognitive dysfunction, cognitive deficits, cognitive biomarkers, cognitive assessment, cognition kit, cognition, cns summit, clinical trials, clinical trial, cias, cgt, cantab research grant, cantab for clinical trials, cantab, brain health, biomarkers, awards, automatic speech recognition, attention, alzheimer's disease, altitude, affective cognition, absenteeism,